Abstract Hydroxyapatite crystals are often deposited in the vicinity of joints, where they can cause a clinical periarthritis. Clodronate is a Wrst-generation bisphosphonate that has the ability to reduce ectopic calciWcations. Two women were aVected by disabling calciWc periarthritis of the shoulders lasting for years and resistant to any traditional drug (including glucocorticoids), inWltration and surgical treatment. We treated both patients with low-dose methylprednisolone added to intramuscular clodronate at the daily dose of 100 mg administered for 20 days every 3 months for 5 cycles (18 months). In both cases, the results were clinically evident within 1 month, showing a signiWcant reduction in pain and disability. After 18 months, the result was furthermore radiologically evident in both cases with a great reduction in the size of calciWcations. These improvements were still present at follow-up after 7 and 5 years with complete functional recovery.
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Case report no 1
A woman began suVering from bilateral shoulder calciWc periarthritis at the age of 35 and was treated with several anti-inXammatory drugs, including high-dose GC per os and intra-articular GC. Nevertheless, she developed a right "frozen shoulder" and underwent surgical treatment of irrigation in arthroscopy with no results. At the age of 44, the plane X-ray of the shoulders showed bilateral coarse calciWcations that reached 3 cm in diameter on the right-hand side.
We diagnosed a hydroxyapatite crystal-deposition disease (HADD). We treated her with low-dose GC (MP 4 mg) added to a cycle of intramuscular clodronate (Clasteon ® , Abiogen Pharma, Pisa, Italy) 100 mg daily for 20 days. Within 30 days, the pain and disability disappeared and the patient's health greatly improved. The treatment continued with complete success for 18 months with MP 2 mg daily added to CLO 100 mg im for 20 days every 3 months. At the end of this period, a new plane X-ray of the right shoulder showed a great reduction in the size of the calciWcation from 3 to 1 cm in diameter (Fig. 1) .
The treatment with low-dose MP (2 mg daily) was then continued. In the next 7 years of follow-up, the patient had 
Case report no 2
A woman began suVering from bilateral calciWc shoulder periarthritis at the age of 30. She was treated with antiinXammatory drugs and intra-articular glucocorticoids obtaining only partial and temporary amelioration. At the age of 54, the left shoulder was aVected by a disabling pain resistant to any traditional therapy.
A plane X-ray of the left shoulder showed a calciWcation with a diameter of 12 mm. We diagnosed an HADD, and we treated her with low-dose GC (MP 2 mg) added to im clodronate (Clasteon ® , Abiogen Pharma, Pisa, Italy) 100 mg daily for 20 days. Within 30 days, the pain and disability disappeared and the patient's health improved greatly. The treatment continued with complete success for 18 months with MP 2 mg daily added to CLO 100 mg im for 20 days every 3 months. At the end of this period, a new plane X-ray of the left shoulder showed a great reduction in the size of the calciWcation (from 12 to 5 mm in diameter) (Fig. 2) .
The treatment with low-dose MP (2 mg daily) was then continued. In the next 5 years of follow-up, the patient had no relapse and could work without any problem. A further plane X-ray demonstrated that calciWcation at the left shoulder still maintains the small size (5 mm).
Discussion
The main characteristics and outcomes of the patients are shown in Table 1 . HADD was identiWed as a new arthropathy in 1976 by Dieppe who recognized it as a third type of crystal-deposition disease [1] . HA crystals are a very common cause of periarticular disease giving rise to acute inXammation of tendons, intervertebral discs, joint capsules, synovium and cartilage [2, 3] .
The shoulder is the most common joint involved in HADD. Clinical symptoms are often represented by chronic pain and restricted joint motion [4] .
Calcifying periarthritis is found in about 3% of adult patients and in up to 17% of painful shoulder syndromes. Rupture of the crystal deposit into the next subacromial bursa is usually followed by an acute disabling pain attack with important reduction in the range of motion. Sometimes crystal deposits may persist for years leading to a chronic shoulder pain probably due to an impingement mechanism. Surgical treatments include the break of the calciWcations or the percutaneous needle aspiration followed by a lavage [5] .
BPs were used primarily as inhibitors of calciWcations and resorption. They are able to bind to HA crystals, thus inhibiting crystal growth [6] . CLO is a Wrst-generation nonnitrogen-containing BP also available in ampoules for im and iv injections. CLO is currently registered for the treatment of post-menopausal osteoporosis, multiple myeloma, primary hyperparathyroidism and cancer osteolysis. Each BP in vitro has a diVerent kinetic binding aYnity for HA, attributed to diVerences in the R2 side chain. These characteristics can explain some of BPs clinical activities [7] .
CLO has a low antiresorptive potency but can be able to inhibit non-skeletal and soft tissues calciWcations both in experimental models and in humans [8] . Moreover, BPs and particularly CLO have been successfully studied to prevent the development of experimental atherosclerosis, because of the ability of CLO to remove calcium from atheromatous lesions [8, 9] . This property is probably linked to CLO's low aYnity for bone and HA. In fact, risedronate, which has the same low aYnity for bone and HA crystals, can prevent ectopic calciWcations in rheumatic patients aVected by CREST syndrome [10] . In conclusion, CLO could be an eVective drug in the treatment of HADD reducing the size of calciWcations with signiWcant clinical improvement; the association with other drugs, as low-dose GC, could help maintaining results even in unresponsive cases.
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